BRIDGE CAR T
Building Bridges Between Treatment Centers and Community Oncologists to Overcome Barriers in CAR T-Cell Therapy
Target Audience
This activity will provide continuing medical education (CME) that addresses identified knowledge and practice gaps among community-based hematologist/oncologist clinicians (MDs, APPs and nurses).
Series Description
Multiple myeloma (MM) is an incurable plasma cell malignancy with a high burden of relapse and treatment resistance. For patients with relapsed/refractory multiple myeloma (RRMM), chimeric antigen receptor (CAR) T-cell therapies have emerged as a promising treatment approach, offering the potential for deep and durable responses; however, timely referral and coordination between community oncologists and specialized CAR T treatment centers remain significant barriers to patient access. BRIDGE CAR T: Building Bridges Between Treatment Centers and Community Oncologists to Overcome Barriers in CAR T-Cell Therapy is a grassroots CME/CE pilot initiative designed to close these gaps by delivering localized, small-group educational workshops, expert-led discussions, and practical clinician and patient support tools. This multifaceted program will equip community hematologist/oncologists with the latest clinical evidence, real-world insights, and practical strategies for optimizing patient selection, referral, and long-term adverse event (AE) management. By fostering sustained connections between community providers and CAR T treatment centers, BRIDGE CAR T aims to streamline care coordination, enhance provider confidence, and ultimately improve outcomes for patients with RRMM.
Educational Objectives
After completing this activity, the participant should be better able to:
- Identify patients with RRMM early in the treatment course who may be eligible for referral to CAR T-cell therapy
- Compare the efficacy and safety profiles of FDA-approved CAR T-cell therapy
- Describe the monitoring, mitigation, and management strategies for potential short- and long-term adverse events associated with CAR T-cell therapy
- Identify and manage long-term CAR T-related adverse events in community clinics
- Develop strategies to improve multidisciplinary care coordination between CAR T-cell treatment centers and community sites to overcome barriers associated with CAR T-cell referral and implementation
- Effectively communicate with patients to explain the benefits and risks related to CAR T-cell therapy
10
2025
Coordination of Care Between Our Center and Yours
| Time: | 5:30 PM-6:30 PM CT |
| Venue: | Webinar |
08
2025
CAR T-cell Therapy: A Case-Based Workshop
| Time: | 5:30 PM-6:30 PM CT |
| Venue: | Webinar |
